The Spark is a Lantern Pharma newsletter that provides succinct and frequent updates about Lantern, our RADR® AI and ML platform, and our pipeline of drug programs. Subscribe to the newsletter to receive it by email or see the most recent editions below.

Lantern Pharma Newsletter December 2022

The December 2022 edition of The Spark features exciting new company updates including:

  • Lantern was ranked as one of the top 20 most productive AI drug development companies worldwide.
  • Harmonic™ trial adds 8 new locations across NY to bolster patient recruitment with New York Cancer and Blood Specialists
  • Interviews of never-smokers with lung cancer highlights needs for new therapies and trials targeted for never-smokers
  • Expansion of LP-184’s development for triple negative breast cancer increases its long-term value
  • New positive LP-284 data for mantle cell lymphoma (MCL) advances it towards a Phase 1 trial in 2023